McCormick Frank

Dr. McCormick Frank


Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Cell
Verified
Journal Article
Closed access
DSDhirendra K Simanshu
Dhirendra K Simanshu
DNDwight V. Nissley
Dwight V. Nissley
MFMcCormick Frank
McCormick Frank

1 November 2017 in Nature
Verified
Journal Article
Open access
PDF file
MHMatthew J. Hangauer
Matthew J. Hangauer
VVVasanthi S. Viswanathan
Vasanthi S. Viswanathan
MRMatthew J. Ryan
Matthew J. Ryan
DBDhruv Bole
Dhruv Bole
JEJohn K. Eaton
John K. Eaton
MMMichael T. McManus
Michael T. McManus
Cancer persister cells, which survive cytotoxic treatments, are shown to be sensitive to inhibition of the lipid hydroperoxidase GPX4. During cancer treatment, tumours can become drug-resistant. In addition, so-called persister cells can emerge and form a reservoir from which resistant cancer cells can originate. Persister cells are no longer sensitive to some drugs, but Michael McManus and colleagues now report that they exist in a mesenchymal state in which they are selectively sensitive to the inhibition of the lipid hydroperoxidase GPX4. Targeting GPX4 could therefore represent a new therapeutic avenue to potentially prevent drug resistance. Acquired drug resistance prevents cancer therapies from achieving stable and complete responses1. Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer ‘persister’ cells2,3,4. The persister cell pool constitutes a reservoir from which drug-resistant tumours may emerge. Targeting persister cells therefore presents a therapeutic opportunity to impede tumour relapse5. We previously found that cancer cells in a high mesenchymal therapy-resistant cell state are dependent on the lipid hydroperoxidase GPX4 for survival6. Here we show that a similar therapy-resistant cell state underlies the behaviour of persister cells derived from a wide range of cancers and drug treatments. Consequently, we demonstrate that persister cells acquire a dependency on GPX4. Loss of GPX4 function results in selective persister cell ferroptotic death in vitro and prevents tumour relapse in mice. These findings suggest that targeting of GPX4 may represent a therapeutic strategy to prevent acquired drug resistance.

19 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
TTTimothy H. Tran
Timothy H. Tran
ACAlbert H. Chan
Albert H. Chan
LYLucy C. Young
Lucy C. Young
LBLakshman Bindu
Lakshman Bindu
CNChris Neale
Chris Neale
DSDhirendra K Simanshu
Dhirendra K Simanshu
The first step of RAF activation involves binding to active RAS, resulting in the recruitment of RAF to the plasma membrane. To understand the molecular details of RAS-RAF interaction, we present crystal structures of wild-type and oncogenic mutants of KRAS complexed with the RAS-binding domain (RBD) and the membrane-interacting cysteine-rich domain (CRD) from the N-terminal regulatory region of RAF1. Our structures reveal that RBD and CRD interact with each other to form one structural entity in which both RBD and CRD interact extensively with KRAS. Mutations at the KRAS-CRD interface result in a significant reduction in RAF1 activation despite only a modest decrease in binding affinity. Combining our structures and published data, we provide a model of RAS-RAF complexation at the membrane, and molecular insights into RAS-RAF interaction during the process of RAS-mediated RAF activation.

24 March 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SMSuman Mukhopadhyay
Suman Mukhopadhyay
MHMatthew G. Vander Heiden
Matthew G. Vander Heiden
MFMcCormick Frank
McCormick Frank

15 April 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
SMSuman Mukhopadhyay
Suman Mukhopadhyay
DGDebanjan Goswami
Debanjan Goswami
PAPavan P. Adiseshaiah
Pavan P. Adiseshaiah
WBWilliam Burgan
William Burgan
MYMing Yi
Ming Yi
MFMcCormick Frank
McCormick Frank
Pancreatic cancer is a disease with limited therapeutic options. Resistance to chemotherapies poses a significant clinical challenge for patients with pancreatic cancer and contributes to a high rate of recurrence. Oncogenic KRAS, a critical driver of pancreatic cancer, promotes metabolic reprogramming and upregulates NRF2, a master regulator of the antioxidant network. Here, we show that NRF2 contributed to chemoresistance and was associated with a poor prognosis in patients with pancreatic cancer. NRF2 activation metabolically rewired and elevated pathways involved in glutamine metabolism. This curbed chemoresistance in KRAS-mutant pancreatic cancers. In addition, manipulating glutamine metabolism restrained the assembly of stress granules, an indicator of chemoresistance. Glutaminase inhibitors sensitized chemoresistant pancreatic cancer cells to gemcitabine, thereby improving the effectiveness of chemotherapy. This therapeutic approach holds promise as a novel therapy for patients with pancreatic cancer harboring KRAS mutation. Significance: These findings illuminate the mechanistic features of KRAS-mediated chemoresistance and provide a rationale for exploiting metabolic reprogramming in pancreatic cancer cells to confer therapeutic opportunities that could be translated into clinical trials.

17 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SDSrisathiyanarayanan Dharmaiah
Srisathiyanarayanan Dharmaiah
LBLakshman Bindu
Lakshman Bindu
TTTimothy H. Tran
Timothy H. Tran
WGWilliam K. Gillette
William K. Gillette
PFPeter H. Frank
Peter H. Frank
DSDhirendra K Simanshu
Dhirendra K Simanshu
Significance: Despite the significant progress made in the last few years toward targeting phosphodiesterase-δ (PDEδ) for KRAS (Kirsten rat sarcoma isoform)-driven cancers, there is no structural information available on posttranslationally modified KRAS4b in complex with PDEδ. The KRAS4b–PDEδ structure reported here provides the structural details of the protein–protein interaction interface and the atomic details of the hypervariable region of KRAS4b. Structural comparison of the two crystal forms allowed identification of a 5-aa-long sequence motif in KRAS4b that could allow PDEδ to bind to both farnesylated and geranylgeranylated KRAS4b. Structural insights obtained from this study could be used to guide the development of improved and more specific inhibitors of the KRAS4b–PDEδ complex.